Montelukast Accord (Montelukast Sodium)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from triggering bronchoconstriction, mucus secretion, and inflammatory cell recruitment, which together reduce airway narrowing and allergic inflammation.

The specific dose is determined by the prescribing clinician based on the patient’s age, weight, and clinical condition. Typical regimens range from once‑daily tablets, but exact strength and frequency must be individualized by a healthcare professional.

Safety data for montelukast in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the prescriber after evaluating the clinical situation.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists for asthma control. Compared with other leukotriene antagonists such as zafirlukast, montelukast has a once‑daily dosing schedule and a broader approval for allergic rhinitis.

Montelukast Accord should be stored at ambient temperature below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to extreme heat or humidity.

The medication is taken orally as a tablet, swallowed whole with a glass of water. It may be taken with or without food, and the dose is usually administered once daily at the same time each day for consistent blood levels.

Serious adverse events include allergic reactions such as angioedema or anaphylaxis, neuropsychiatric effects like depression or suicidal thoughts, and rare hepatic injury. Patients should be instructed to seek immediate medical attention if they experience any of these symptoms.

Montelukast is contraindicated in individuals with known hypersensitivity to montelukast sodium or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment or those who have experienced previous serious reactions to leukotriene receptor antagonists.